Ondine Biomedical Inc.
London Stock ExchangeTotal Valuation
Ondine Biomedical Inc. carries a market capitalization of 65.71M, placing it among publicly traded companies globally. Its enterprise value stands at 1.68M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 65.71M |
| Enterprise Value | 1.68M |
Share Statistics
Ondine Biomedical Inc. currently has 9.66M shares outstanding.
| Shares Outstanding | 9.66M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Enterprise Valuation
| EV / Sales | 0.83 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Ondine Biomedical Inc. maintains a current ratio of 0.41, meaning it holds 0.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -138.07, indicating conservative leverage, while an interest coverage ratio of -310.10 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.41 |
| Quick Ratio | 0.31 |
| Debt / Equity | -138.07 |
| Debt / EBITDA | -0.65 |
| Interest Coverage | -310.10 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -137.34 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 1.96 |
Taxes
| Income Tax | 997.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
Ondine Biomedical Inc.'s stock has gained approximately 8.36364% over the past 52 weeks. The 50-day moving average sits at 14.13, while the 200-day moving average is 11.59.
| Beta (5Y) | N/A |
| 52-Week Price Change | 8.36364% |
| 50-Day Moving Average | 14.13 |
| 200-Day Moving Average | 11.59 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Ondine Biomedical Inc. generated 2.02M in revenue and converted that into -3.22M in net income, yielding earnings per share of -0.07. EBITDA reached -3.88M, while operating income came in at -4.15M.
| Revenue | 2.02M |
| Gross Profit | 1.52M |
| Operating Income | -4.15M |
| Pretax Income | -3.22M |
| Net Income | -3.22M |
| EBITDA | -3.88M |
| EBIT | -4.15M |
| Earnings Per Share (EPS) | -0.07 |
Balance Sheet
Ondine Biomedical Inc. holds 834,854.00 in cash and equivalents against 2.51M in total debt, resulting in a net debt position of 1.68M. Total book value stands at -64.52M, with working capital of -2.42M providing operational flexibility.
| Cash & Cash Equivalents | 834,854.00 |
| Total Debt | 2.51M |
| Net Debt | 1.68M |
| Equity (Book Value) | -64.52M |
| Book Value Per Share | -1.32 |
| Working Capital | -2.42M |
Cash Flow
Ondine Biomedical Inc. produced -3.04M in operating cash flow over the past twelve months. After subtracting -132,667.00 in capital expenditures, free cash flow totaled -3.17M - equivalent to -0.07 per share.
| Operating Cash Flow | -3.04M |
| Capital Expenditures | -132,667.00 |
| Free Cash Flow | -3.17M |
| FCF Per Share | -0.07 |
Margins
Ondine Biomedical Inc. operates with a gross margin of 75.25, reflecting its pricing power and cost economics. The operating margin of -205.78 and net profit margin of -159.67 provide insight into operational efficiency.
| Gross Margin | 75.25 |
| Operating Margin | -205.78 |
| Pretax Margin | -159.62 |
| Profit Margin | -159.67 |
| EBITDA Margin | -192.18 |
Scores
Ondine Biomedical Inc. posts an Altman Z-Score of -51.16, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -51.16 |